Literature DB >> 25279502

Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Henrik Falhammar1, Louise Frisén, Christina Norrby, Angelica Lindén Hirschberg, Catarina Almqvist, Agneta Nordenskjöld, Anna Nordenström.   

Abstract

CONTEXT: Reports on mortality in patients with congenital adrenal hyperplasia (CAH) are lacking.
OBJECTIVE: This study sought to study mortality and causes of death in CAH. DESIGN, SETTING, AND PARTICIPANTS: We studied patients with CAH (21-hydroxylase deficiency, n = 588; CYP21A2 mutations known, >80%), and compared them with controls (n = 58 800). Data were derived through linkage of national population-based registers. MAIN OUTCOME MEASURES: Mortality and causes of death.
RESULTS: Mean age of death was 41.2 ± 26.9 years in patients with CAH and 47.7 ± 27.7 years in controls (P < .001). Among patients with CAH, 23 (3.9%) had deceased compared with 942 (1.6%) of controls. The hazard ratio (and 95% confidence interval) of death was 2.3 (1.2-4.3) in CAH males and 3.5 (2.0-6.0) in CAH females. Including only patients born 1952-2009, gave similar total results but only patients with salt wasting (SW) or with unclear phenotype had an increased mortality. The causes of death in patients with CAH were adrenal crisis (42%), cardiovascular (32%), cancer (16%), and suicide (10%). There were seven additional deaths in CAH individuals with incomplete or reused personal identification number that could not be analyzed using linkage of registers. Of the latter, all except one were deceased before the introduction of neonatal screening in 1986, and most of them in the first weeks of life, probably in an adrenal crisis.
CONCLUSIONS: CAH is a potentially lethal condition and was associated with excess mortality due to adrenal crisis. The SW phenotype also seemed to have worse outcome in children and adults due to adrenal crisis and not only before the introduction of neonatal screening.

Entities:  

Mesh:

Year:  2014        PMID: 25279502     DOI: 10.1210/jc.2014-2957

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  47 in total

Review 1.  The way toward adulthood for females with nonclassic congenital adrenal hyperplasia.

Authors:  Georgia Ntali; Sokratis Charisis; Christo F Kylafi; Evangelia Vogiatzi; Lina Michala
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

Review 2.  Adrenal insufficiency.

Authors:  Stefanie Hahner; Richard J Ross; Wiebke Arlt; Irina Bancos; Stephanie Burger-Stritt; David J Torpy; Eystein S Husebye; Marcus Quinkler
Journal:  Nat Rev Dis Primers       Date:  2021-03-11       Impact factor: 52.329

Review 3.  Monogenic Disorders of Adrenal Steroidogenesis.

Authors:  Elizabeth S Baranowski; Wiebke Arlt; Jan Idkowiak
Journal:  Horm Res Paediatr       Date:  2018-06-06       Impact factor: 2.852

Review 4.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 5.  Adrenal crises: perspectives and research directions.

Authors:  R Louise Rushworth; David J Torpy; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-19       Impact factor: 3.633

Review 6.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

Review 7.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

8.  Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With Congenital Adrenal Hyperplasia.

Authors:  Diala El-Maouche; Courtney J Hargreaves; Ninet Sinaii; Ashwini Mallappa; Padmasree Veeraraghavan; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958

9.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 10.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.